LI-ESWT: The Effect of Low Intensity Shockwave Therapy for ED in Post Radical Prostatectomy Patients Who Didn't Respond to PDE5i
Study Details
Study Description
Brief Summary
Low Intensity Shock Wave Therapy (LI-ESWT) was shown to have a beneficial effect on ED patients responding to PDE5i's. This study aimed to determine the capability of LI-ESWT to affect patients who underwent radical prostatectomy who did not respond to PDE5 inhibitor therapy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
We included severe ED patients that underwent radical prostatectomy at least one year previously and failed to respond to PDE5i therapy, who scored 0-2 on the rigidity scale (RS) during PDE5i therapy. Treatment included 2 sessions/week for 3 weeks, repeated after a 3-week no-treatment interval. At each session LI-ESWT was applied on the penile shaft and crus for 3 minutes in 5 different penile anatomical sites (intensity of 0.09 mj/mm2, 300 shocks/site). One-month after end of treatment the same baseline assessment was repeated. An active PDE5i medication regime was then provided and final erectile function was reassessed. Main endpoints for success were changes in RS and in the International Index of Erectile Function (IIEF-ED) Domain score. This study further emphasises the need to study specific populations with unique etiologies causing ED.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: LI-ESWT Low intensity shock wave treatment- 12 sessions |
Device: LI-ESWT
Low intensity shock wave treatment - 12 sessions
Other Names:
|
Outcome Measures
Primary Outcome Measures
- IIEF-ED Domain score [17 weeks after first visit]
Change of 5 points and above in IIEF-ED Domain score
Secondary Outcome Measures
- Rigidity scale [17 weeks after first visit]
a change to 3 or 4 points in the rigidty scale
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Post Radical prostatectomy
-
ED of more than 6 months
-
Rigidity score ≤ 2 during PDE5i therapy
-
Stable heterosexual relationship for more than 3 months
-
Patients need to know and to agree that the study protocol does not allow any PDE5I therapy till week 13 .
Exclusion Criteria:
-
Prior surgery or radiotherapy in pelvic region
-
Any unstable, psychiatric, spinal cord injury and penile anatomical abnormalities
-
Clinically significant chronic hematological disease
-
Anti-androgens, oral or injectable androgens
-
Cardiovascular conditions that prevent sexual activity
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | neuro-urology unit, Rambam Medical Center | Haifa | Israel |
Sponsors and Collaborators
- Rambam Health Care Campus
- Medispec
Investigators
- Study Director: Ilan Gruenwald, MD, Rambam Medical Investigator
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 3060 radical